30
Participants
Start Date
November 30, 2015
Primary Completion Date
May 16, 2018
Study Completion Date
June 30, 2018
IMO-8400 Dose Group 1
IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
IMO-8400 Dose Group 2
IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
Placebo
normal saline subcutaneous injections once a week for 24 weeks.
Northwell Health, Great Neck
University of Pittsburgh, Pittsburgh
George Washington University, Washington D.C.
Johns Hopkins University, Baltimore
Medical University of South Carolina, Charleston
University of Miami, Miami
University of Alabama, Birmingham
Ohio State University, Columbus
University of Michigan, Ann Arbor
Northwestern University, Chicago
Washington University, St Louis
University of Kansas, Kansas City
Phoenix Neurological Associates, Phoenix
University of California, Irvine, Irvine
Stanford Hospital and Clinics, Stanford
Brigham and Women's Hospital, Boston
University of Vermont College of Medicine, Burlington
University of Debrecen, Debrecen
MRC/ARUK Institute of Ageing and Chronic Disease, University of Liverpool, Liverpool
University College London Hospital, London
Lead Sponsor
Idera Pharmaceuticals, Inc.
INDUSTRY